Neurologia Argentina最新文献

{"title":"Tratamiento de la esclerosis múltiple: situación a octubre del 2020 en los hospitales públicos de Costa Rica","authors":"Johana Vásquez-Céspedes ,&nbsp;Kenneth Carazo-Céspedes ,&nbsp;Huberth Fernández-Morales ,&nbsp;Andreina Moraga-López ,&nbsp;Juan A. Valverde-Espinoza","doi":"10.1016/j.neuarg.2023.10.002","DOIUrl":"10.1016/j.neuarg.2023.10.002","url":null,"abstract":"<div><h3>Introduction</h3><p>In recent years, multiple treatments for multiple sclerosis have emerged for both, injectable and oral routes of administration. Most of these medications are currently available in Costa Rica. However, interferons are still the only available treatment in the public health system. An overwhelming administrative procedure is required to justify the purchase of the rest of the options in case they are needed for any specific patient.</p></div><div><h3>Objective</h3><p>To describe the treatment of multiple sclerosis in Costa Rica.</p></div><div><h3>Patients and methods</h3><p>A longitudinal, observational and retrospective study of cases with the diagnosis of multiple sclerosis in the Costa Rican public hospital system was carried out between 1990 and December 2017. Drug treatment as of October 2020 was analyzed for those patients who met the 2010 McDonald's criteria.</p></div><div><h3>Results</h3><p>A total of 448 cases were obtained, of which 437 were under drug treatment. The most frequent used drugs were Interferón β1-a intramuscular (53.6%), Interferón β1-b (21.2%) and Interferón β1-a subcutaneous (7.9%). By 2020, 163 patients (36.4%) had continued with the first medication, meanwhile 274 persons (62.3%) needed a change of drug. Treatment failure was the main cause of change and fingolimod was the main alternative choice. Interferón β1-a intramuscular has a longer time of use and less change rate, while fingolimod and Interferón β1-a subcutaneous are more likely to require change in a shorter period of time.</p></div><div><h3>Conclusion</h3><p>In Costa Rica, interferons are the most widely used treatments for multiple sclerosis in the public health system. Therapeutic failure is the main reason for changing medication, while fingolimod is the treatment of choice in most cases.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"16 1","pages":"Pages 1-8"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138619521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisión sobre nuevos enfoques de terapias de neurorrehabilitación para pacientes con trastornos neurológicos mediante dispositivos de pedaleo","authors":"Alfredo Lobaina Delgado ,&nbsp;Denis Delisle-Rodriguez ,&nbsp;Adson Ferreira da Rocha ,&nbsp;Elizabeth Salvador Figueroa ,&nbsp;Alberto López-Delis","doi":"10.1016/j.neuarg.2024.02.001","DOIUrl":"https://doi.org/10.1016/j.neuarg.2024.02.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Currently there are several neurorehabilitation therapies for people with motor impairments caused by neurological disorders. Therapies based on pedaling devices have stood out for their advantages for the recovery of motor function, the prevention or treatment for respiratory and cardiovascular complications, and the induction of neuroplasticity. The Brain Computer Interface (BCI) systems constitute new approaches to provide a rehabilitation that actively involves the patient in therapy and is capable of controlling robotic devices such as stationary bicycles or motorized pedals with their own neural signals.</p></div><div><h3>Aim</h3><p>Reflect the current state of BCI systems that use pedaling devices for the therapy of patients with neurological disorders.</p></div><div><h3>Methods</h3><p>A systematic review was carried out in the PubMed and Science Direct databases and other sources such as IEEEXplore, Sensors magazine and Springer publishing house. Original studies and case reports from the last 10 years based on ICC systems for classification of imaginary pedaling movement from EEG signals were included; in healthy subjects and patients with neurological diseases. Papers that did not show quantitative results from metrics such as accuracy during evaluation were excluded. Risk of bias was assessed using the Critical Appraisal Skills Program (CASP).</p></div><div><h3>Results</h3><p>8 studies that met all eligibility requirements were included. The population of healthy subjects was 43, compared to 6 patients with cerebrovascular accident (CVA) and spinal cord injury (SCI). One of the current limitations of community ICC studies is the scarcity of subjects for the evaluation of different methodologies. The investigations not only yielded quantitative results regarding the performance of the implemented computational algorithms, but also the cortical effects they have produced during cycling as a rehabilitation therapy.</p></div><div><h3>Discussion</h3><p>Various authors have shown that treatment with pedaling devices modulates brain and muscle activity. Hence, there are patterns or characteristics during real or imagined pedaling movements. From this information, which can be extracted from surface myoelectric signals (sEMG) or electroencephalography (EEG), it is possible to detect pedaling movement intention, and to control devices for these purposes, many of which are already available in the market.</p></div><div><h3>Conclusion</h3><p>Research about BCI systems based on the detection of imaginary pedaling movement is recent and has achieved a remarkable performance in classification. Commercial devices have yet to incorporate the use of motor imagery therapy.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"16 1","pages":"Pages 31-43"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140160920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estudio de variables demográficas, clínicas y pronósticas en adultos mayores con status epiléptico: análisis comparativo entre diferentes grupos etarios","authors":"María Florencia Sica ,&nbsp;Carla Agustina Holgado ,&nbsp;Lucas Martin Romano ,&nbsp;Iván Roa ,&nbsp;Lucas Piedrafita ,&nbsp;Nicolas Pellice ,&nbsp;Nicolas Kokos ,&nbsp;Agustina Britos ,&nbsp;María Emilia Sanchez ,&nbsp;María Macarena Bermejo ,&nbsp;Daiana Barrio ,&nbsp;Sergio Eduardo Gonorazky ,&nbsp;Alejandro Fernández ,&nbsp;Pablo Ioli ,&nbsp;María Emilia Clement","doi":"10.1016/j.neuarg.2024.01.001","DOIUrl":"10.1016/j.neuarg.2024.01.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Status epilepticus (SE) is a neurological emergency. Certain clinical features and personal patient history have prognostic utility and could contribute to therapeutic decision-making.</p></div><div><h3>Objectives</h3><p>To describe the demographic and clinical characteristics in patients ≥<!--> <!-->65<!--> <!-->years divided into subgroups. To define predictive and prognostic variables.</p></div><div><h3>Material and methods</h3><p>A retrospective observational study was conducted on all cases of convulsive (CSE) and non-convulsive (NCSE) SE admitted to the Hospital Privado de Comunidad between 2006 and 2013. Age groups were subcategorized according to the World Health Organization (WHO): 65-74<!--> <!-->years (G1), 75-84<!--> <!-->years (G2), and ≥<!--> <!-->85<!--> <!-->years (G3).</p></div><div><h3>Results</h3><p>A total of 289 patients with SE aged ≥<!--> <!-->65<!--> <!-->years were recorded. 84 patients (29.1%) belonged to G1, 141 (48.8%) to G2, and 64 (22.1%) to G3. Females were the most prevalent gender. G3 had the lowest percentage of epilepsy history (9.4%). There was no difference in the CSE-vs-NCSE ratio between the groups. Cerebrovascular disease (CVD) was the most prevalent presentation in the groups, with a higher low-dose of antiepileptic drugs in G1 (<em>P</em> <!-->=<!--> <!-->.08). 30-day lethality was 46.8% (G3), 30.9% (G1), and 36.2% (G2) (<em>P</em> <!-->=<!--> <!-->.13). G1 patients had a higher recurrence rate (<em>P</em> <!-->=<!--> <!-->.001). The total hospitalization cost was higher for G1 (<em>P</em> <!-->=<!--> <!-->.005).</p></div><div><h3>Conclusion</h3><p>There is a trend to present SE as the first crisis in G3. SE in the elderly tends to occur without a history of epilepsy. The most frequent acute symptomatic cause is CVD. Age is a poor prognostic factor. Hence, the importance of this study in providing data related to this pathology in older adults.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"16 1","pages":"Pages 15-21"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139965704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Síntomas gastrointestinales inespecíficos como forma de presentación de polineuropatía amiloidótica familiar PAF-TTR. Reporte de un caso","authors":"Esteban Leonardo Calabrese,&nbsp;German Victor Ramon Calabrese","doi":"10.1016/j.neuarg.2023.10.001","DOIUrl":"https://doi.org/10.1016/j.neuarg.2023.10.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Familial transthyretin amyloidotic polyneuropathy (FAP-TTR), an autosomal dominant disease. It generally manifests with cardiomyopathy and polyneuropathy, however, gastrointestinal (GI) symptoms are common. We report a patient with AF-TTR and initial GI symptoms.</p></div><div><h3>Clinical case</h3><p>A 67-year-old man presented with burning neuropathic pain. History, diarrhea alternating with constipation and weight loss, diagnosis of irritable bowel. Physical examination alteration of hot-cold sensitivity tests. Sensorimotor axonal polyneuropathy nerve conduction study. Transthyretin gene analysis heterozygous variant p.Val50Met, PAF-TTR diagnosis.</p></div><div><h3>Conclusions</h3><p>The non-specificity of GI symptoms at the onset of the condition is a challenge in the diagnostic suspicion of this entity.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"15 4","pages":"Pages 299-303"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138821944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilidad de la identificación de anticuerpos en miopatías inflamatorias: revisión","authors":"Laura Pirra ,&nbsp;Belen Tillard ,&nbsp;Paz Zuberhbuler ,&nbsp;Elisa Cisneros ,&nbsp;Mariana Bendersky ,&nbsp;Luciana León Cejas ,&nbsp;Florencia Aguirre ,&nbsp;Valeria Alvarez ,&nbsp;Fabio Barroso ,&nbsp;Andrés Berardo ,&nbsp;Mariela Bettini ,&nbsp;Mariano Borrelli ,&nbsp;Marcelo Chaves ,&nbsp;Fernando Chloca ,&nbsp;José Crespo ,&nbsp;Marianna di Egidio ,&nbsp;Alberto Dubrovsky ,&nbsp;María Alejandra Figueredo ,&nbsp;Gisella Gargiulo ,&nbsp;Agustín Jáuregui ,&nbsp;Eugenia Conti","doi":"10.1016/j.neuarg.2023.11.001","DOIUrl":"https://doi.org/10.1016/j.neuarg.2023.11.001","url":null,"abstract":"<div><h3>Introduction</h3><p>The discovery of specific autoantibodies meant a significant milestone in mainly idiopathic inflammatory myopathies (IIM) diagnosis. This granted serological findings to be taken into account along with traditional ones – as clinical and histopathological – in diagnosis criteria, resulting in a new classification consensus.</p></div><div><h3>Objectives</h3><p>To describe myositis-specific antibodies (AEM) and myositis-associated antibodies (AAM), to describe methodologies for AEM and AAM identification, to define their utility and convenience in daily clinical practice.</p></div><div><h3>Development</h3><p>AEMs are classified as follows: anti-aminoacyl-tRNA synthetases (AAS), anti-Mi-2 (nucleosome remodeling deacetylase complex), anti-SRP (signal recognition particle), anti-TIF1γ (transcription intermediary factor 1γ), anti-NXP-2 (Nuclear Matrix Protein 2), anti-MDA5 (Melanoma Differentiation Associated Gene 5), anti-SAE (Small ubiquitin-like modifier activating-enzyme), anti-HMGCR (3-Hydroxy-3-methylglutaryl-CoA reductase) and anti-cN-1A (Cytosolic 5′-nucleotidase 1A) and MAA: anti-PM/Scl (Exosome Protein Complex PM/Scl75/100), anti-U1-RNP (U1 small nuclear RNP), anti-Ku (DNA-PK regulatory subunit), anti-Ro/SSA (Sjögren's syndrome related antigen A).</p></div><div><h3>Conclusions</h3><p>The incorporation of serological criteria in IIM diagnosis criteria led to a new classification consensus, resulting in the tracing and identification of homogeneous patient populations. Such outline provides an opportunity to improve and empower clinical trials when it comes to determine treatments directed to different patient subgroups.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"15 4","pages":"Pages 288-298"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138821917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valores normativos para el Cuestionario de Quejas Cognitivas para adultos entre 30 y 90 años","authors":"Diana Bruno ,&nbsp;Veronica Fernandez ,&nbsp;Florencia Portillo ,&nbsp;Solange Llarena Nuñez","doi":"10.1016/j.neuarg.2023.09.001","DOIUrl":"10.1016/j.neuarg.2023.09.001","url":null,"abstract":"<div><h3>Introduction</h3><p>The Cognitive Complaints Questionnaire (CCQ) has proven to be a valid and reliable instrument according to expert judgment and concurrent validity analysis with objective measures, to assess people's cognitive complaints. This is important when considering them as a possible indicator of cognitive deterioration. In order to facilitate the interpretation and comparison of the results of the instrument, it is necessary not only that it present good psychometric properties, but also that it be standardized and regulated.</p></div><div><h3>Objective</h3><p>Generate normative values for the CCQ in a sample of adults between 30 and 90 years of age from Argentine.</p></div><div><h3>Subjects and method</h3><p>Quantitative approach of instrumental type. The sample included 230 healthy people, residents in Argentina, with no psychiatric or neurological history.</p></div><div><h3>Results</h3><p>Correlations were observed between the CCQ and age and years of formal education, for this reason the normative values of the CCQ were organized by groups according to age and years of formal education. For age groups were divided into 2, one from 30 to 70 years and the other from 71 to 90 years. And for the years of formal education, 3 groups were formed: less than 7 years, between 7 and 15 years, and more than 15 years. The analysis of the psychometric properties once again yielded very good internal consistency and validity indices. Normative values are presented.</p></div><div><h3>Conclusion</h3><p>The CCQ is a useful instrument for exploring cognitive complaints.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"15 4","pages":"Pages 271-278"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135849321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relevamiento de recursos disponibles para el manejo de status epiléptico en centros asistenciales en Argentina","authors":"Viviana Ibarra ,&nbsp;Cristina Papayannis ,&nbsp;María Belén Viaggio ,&nbsp;Lucas Romano ,&nbsp;Ricardo Bernater ,&nbsp;Mónica Perassolo ,&nbsp;Vanesa Roig ,&nbsp;Analía Calle","doi":"10.1016/j.neuarg.2023.08.001","DOIUrl":"10.1016/j.neuarg.2023.08.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Status epilepticus (SE) is a neurological emergency that requires prompt diagnosis and treatment due to its high morbidity and mortality. Knowing the availability of local diagnostic and treatment resources is important for improving therapeutic outcomes through effective strategies.</p></div><div><h3>Objective</h3><p>To assess the resources available for the diagnosis and treatment of SE in hospitals in the Argentine Republic.</p></div><div><h3>Materials and methods</h3><p>The Epilepsy Working Group of the Argentine Neurological Society distributed a voluntary semi-structured survey to 51 representative centers for the care of patients with SE in July 2021. Information was requested regarding the healthcare model, pharmacological protocols for different phases of SE, and available electroencephalographic resources.</p></div><div><h3>Results</h3><p>Regarding the early stage of SE, we found that there is adequate availability of antiseizure medications (ASMs) in both public and private centers, with lorazepam being the most commonly chosen drug. Regarding the treatment choice for established SE, we found that phenytoin is the most commonly used in public hospitals, while levetiracetam is the preferred choice in nonpublic hospitals, and this difference is statistically significant (<em>p</em> &lt; 0.0001). There was a low availability of EEG monitoring in both settings, although there was a greater availability of prolonged monitoring in private centers (<em>p</em> = 0.0003).</p></div><div><h3>Conclusion</h3><p>This study provides information about the available resources in our country for the management of SE and allows for the development of educational and management strategies to improve its diagnosis and treatment.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"15 4","pages":"Pages 261-270"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135607304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Características clínicas y demográficas de los pacientes con enfermedades desmielinizantes en Ecuador","authors":"Patricio Alexander Merino Aguilera ,&nbsp;Edgar Patricio Correa Díaz ,&nbsp;Ruth Jimbo Sotomayor ,&nbsp;Jorge Rubén Pilco Romero","doi":"10.1016/j.neuarg.2023.11.002","DOIUrl":"https://doi.org/10.1016/j.neuarg.2023.11.002","url":null,"abstract":"<div><h3>Introduction</h3><p>MS and NMOSD are chronic demyelinating diseases mediated by the immune system, related to demyelinating attacks on the brain, optic nerve and spinal cord, which can cause severe disability in young people. In LATAM there is few reports on the demographic and clinical characteristics of both diseases.</p></div><div><h3>Objective</h3><p>To establish and compare the clinical and demographic characteristics of MS and NMOSD patients.</p></div><div><h3>Materials and methods</h3><p>This is a descriptive and transversal study which included MS and NMOSD patients who were attended in the Carlos Andrade Marin hospital in Quito, Ecuador. Univariate and multivariate analysis were performed using SPSS.</p></div><div><h3>Results</h3><p>We included 151 patients with MS and NMOSD, the predominant sex in the two diseases was female, mestizo ethnicity was common in both diseases, higher education was frequent in both conditions specially in MS. The average age was 42.3 years in EM and 49.8 years in TENMO (<em>p</em> &lt; 0.005). Fatigue was more common in MS than NMOSD. There was a predominance of mild disability in EM and moderate disability in TENMO with a mean of EDSS 2.5 and 4.2, respectively (<em>p</em> &lt; 0.005). The presence of comorbidities was infrequent in both diseases.</p></div><div><h3>Conclusión</h3><p>The clinical and demographic characteristics in our study is very similar to finding around the world. However, the mestizo ethnicity was common in both conditions. We found lower frequency of fatigue, motor and sensory symptoms in comparison with previous reports. NMOSD patients had higher disability than MS patients.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"15 4","pages":"Pages 279-287"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138821942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Profesor Rolando Juvenal Giannaula (16 agosto 1953-26 enero 2023)","authors":"","doi":"10.1016/j.neuarg.2023.11.003","DOIUrl":"https://doi.org/10.1016/j.neuarg.2023.11.003","url":null,"abstract":"","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"15 4","pages":"Pages 306-307"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1853002823000708/pdfft?md5=2447638aae94ca0ff206d3e5aaedd2bf&pid=1-s2.0-S1853002823000708-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138821943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"La falacia de la «experiencia vs. evidencia»","authors":"Andrés Barboza","doi":"10.1016/j.neuarg.2023.07.006","DOIUrl":"10.1016/j.neuarg.2023.07.006","url":null,"abstract":"","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"15 4","pages":"Pages 304-305"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134935535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}